摘要
Abstract: The Blood-Brain Barrier (BBB) poses a significant obstacle to the delivery of therapeutic agents to the Central Nervous System (CNS), complicating treatment for neurological disorders such as Alzheimer's, Parkinson's, and epilepsy. Intranasal (IN) delivery has emerged as a promising non-invasive method to bypass the BBB, utilizing the nasal cavity's unique anatomy to achieve direct drug transport to the brain. This route minimizes systemic side effects and avoids first-pass metabolism. Key mechanisms include transport via the olfactory and trigeminal nerves, facilitating rapid and efficient delivery of small, lipophilic, and nanoparticle-encapsulated drugs. Recent advancements in nanotechnology have enhanced IN drug delivery, offering improved bioavailability, targeting specificity, and prolonged residence time in the nasal mucosa. Nanoparticles such as lipid carriers and polymer-based systems have demonstrated potential in overcoming mucociliary clearance, enzymatic degradation, and tight junction barriers. Furthermore, innovative delivery devices, including atomizers and pressurized systems, have optimized deposition in the olfactory region, increasing therapeutic efficacy. Challenges remain, including limited nasal cavity volume, formulation stability, and variability in patient anatomy. Strategies such as permeation enhancers, mucoadhesive agents, and enzyme inhibitors are under investigation to mitigate these barriers. Preclinical and clinical studies highlight the potential of IN delivery systems in revolutionizing CNS treatment by providing targeted, efficient, and less invasive therapeutic options. This paper reviews recent developments, focusing on the application of nanoparticle-based formulations for nose-to-brain drug delivery, underscoring their promise in addressing unmet clinical needs.